Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
|
|
- Godfrey Cox
- 5 years ago
- Views:
Transcription
1 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011
2 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai Motor s management, our use of the words expect, anticipate, project, estimate, forecast, objective, plan, goal, outlook, target, pursue and similar expressions is intended to identify forward looking statements. The financial data discussed herein are presented on a preliminary basis before the audit from Independent Auditor; final data will be included in HMC s Independent auditors report. While these statements represent our current judgment on what the future may hold, and we believe these judgments are reasonable, actual results may differ materially due to numerous important factors. Such factors include, among others, the following : changes in economic conditions, currency exchange rates or political stability; shortages of fuel, labor strikes or work stoppages; market acceptance of the corporation s new products; significant changes in the competitive environment; changes in laws, regulations and tax rates; and the ability of the corporation to achieve reductions in cost and employment levels to realize production efficiencies and implement capital expenditures at levels and times planned by management. We do not intend or assume any obligation to update any forward-looking statement, which speaks only as of the date on which it is made.
3 Table of Contents Sales Summary Financial Summary Revenue & Profit Analysis Appendix
4 Sales Summary Retail Sales Wholesale
5 Sales Summary : Retail Sales 1Q Q 2011 (Unit : 1,000 vehicles) -0.8% +29.3% +27.9% +0.01% Korea EU China +10.0% US +4.7% Others 1Q 2010 Global Sales 1Q 2011 Source : Company data (Includes shipment of LCV / Excludes CKD sales) 5
6 Sales Results by Key Region Korea US US (Unit : 1,000 vehicles) EU EU 48.1% 46.0% 4.4% 4.7% 2.7% 2.8% -0.8% % % Q Q 2011 PC RV CV M/S 1Q Q 2011 PC RV M/S 1Q Q 2011 PC RV CV M/S Unit sales in 10.1Q slightly declined due to the high base effect (YOY 0.8% ) Large-car segment sales increased with introduction of HG (YOY 60% ) Launched MD successfully while YF continues to maintain high level of customer demand Lowest level of incentive spending ( 11.1Q : $1,117 / units) Despite of market demand decrease in 1Q, sales of ix20 and ix 35 increased Sales growth in Germany (YoY 41% ) mitigated demand decrease in EU Source : Company data / Automotive News / ACEA 6
7 Sales Summary : Wholesale Sales Volume by by Plant Sales Mix Mix by by Segment (Unit : 1,000 vehicles) % 919 7% 8% KOREA CHINA INDIA 17% 17% 18% 18% CV RV US CZECH TURKEY Mid-Large PC Small PC RUSSIA 58% 57% 1Q Q Q Q 2011 Sales volume by plant (Wholesale basis) 7
8 Financial Summary (K-IFRS) Statement of Income Financial Summary by division Statement of Financial Position Cash Flow Highlights
9 Consolidated Statement of Income (KRW Billion) 1Q Q 2011 Change Sales Revenue Gross Profit Margin (%) SG&A Portion (%) Other Operating Income Operating Profit Margin (%) Recurring Profit Margin (%) Net Profit Margin (%) Depreciation Amortization EBITDA 15,021 3, , , , , ,806 18,233 4, , , , , ,367 3, Consolidated Statement of Income (K-IFRS), Business results of BHMC is accounted in equity income accounting Net Profit includes non-controlling interest 9
10 Financial Summary by Division (KRW Billion) 1Q Q 2011 Change Sales Revenue 15,021 18,233 3,212 Automotive 12,511 15,541 3,031 Finance 1,665 1, Other Operating Profit 1,256 1, Automotive 899 1, Finance Other Consolidation adjustment Consolidated Statement of Income (K-IFRS) 10
11 Consolidated Statement of Financial Position (KRW Billion) Q 2011 Change Assets 94,714 97,808 3,094 Current Assets 43,520 47,514 3,994 Cash & Cash Equivalents* 13,638 15,642 2,004 Liabilities 61,826 63,302 1,476 Current Liabilities 31,446 32, Short & Long-Term Debt 38,596 39, Warranty Provision 5,986 6, Equity 32,888 34,506 1,618 Current Ratio (%) Debt / Equity Ratio (%) Net Cash 24,959 23,590 1,369 EBITDA / Interest Expense 10.6 x 17.2 x Consolidated Statement of Financial Position (K-IFRS) Cash & Cash Equivalents : Cash & cash equivalents + Short-term financial instruments 11
12 Consolidated Cash Flow Highlights (KRW Billion) + 1, ,357 6,216 Depreciation / Amortization Tangible / Intangible asset Dividend payment Other Net Income Beginning Cash Balance Ending Cash Balance Consolidated Cash Flow Highlights (K-IFRS) Above figures includes consolidation adjustments by business division (Automotive / Finance / Others) 12
13 Revenue & Profit Analysis Sales Revenue Analysis COGS and SG&A Net Non-Operating Income
14 Sales Revenue Analysis Sales Revenue Positive // Negative Contributors (KRW Billion) Positive Factors 15,021 18, ,212 ( 21.4% ) Improved overseas sales & mix : Unit sales : + 9.2% (842, ,130) 15,541 12,511 Negative Factors KRW appreciation against the USD USD / KRW 1, ,119.3 (2.2% ) 1,665 1, Q Q 2011 KRW appreciation against the EUR EURO / KRW 1, ,540.4 (2.3% ) Automotive Finance Others Consolidated sales revenue excludes sales revenue of BHMC Consolidated sales revenue by business division (Automotive / Finance / Others) 14
15 COGS and SG&A COGS 77.7% 77.2% SG&A and Other Operating Income // Expense (% of Revenue) (% of Revenue, KRW billion) SG & A Salary & wage Marketing Expense Sales warranties Warranty Provision other Other income/ expense (net) F/X transactions 2,165 2, % 5.4% 0.5% 1.3% 4.6% 10.8% 2, % 4.8% 0.4% 1.6% 4.0% 2,434 other % 0.1% 0.1% 0.5% 105 1Q Q Q Q 2011 Consolidated Statement of Income (K-IFRS) 15
16 Net Non-Operating Income (KRW Billion) Financial Income Financial Expense Equity Earnings Q Q Q Q Q Q Q 2010 : Net Non-Operating Income 1Q 2011 : Consolidated Statement of Income (K-IFRS) 16
17 Appendix Changes in accounting policy - Major changes under K-IFRS - Scope of consolidation changes - K-IFRS vs. K-GAAP (Standalone) Overseas Plant Operations
18 Major changes under K-IFRS Changes under K-IFRS Scope of Consolidation Recognition of Account Receivable Employee Benefit Accrued Liabilities Valuation Borrowing Cost Investment Property - Consolidation standard : more than 50% of equity or owns effective management control [largest shareholder with more than 30% shareholding NOT consolidated, SPC consolidated] - Account receivables with recourse to drawers (D/A, L/C, etc) are recognized as liabilities. Previously under K-GAAP they were not recognized as liabilities. - Use actuarial approach to determine amount of allowance for severance liability and long-term employment benefit. - The provision value is discounted with current market discount. - From the date of implementation of the new Standard, Borrowing costs related to the acquisition, construction or production of qualifying asset are capitalize as part of the cost of that asset. - Property held to earn rental income or profit taking purpose are classified as investment property. Previously under K-GAAP, it was classified as tangible asset. 18
19 Scope of consolidation changes Scope of consolidation under K-IFRS : 74 companies (Equity Method affiliates: 33 companies) Consolidation Company Name included (Total 23 companies) Hyundai ngv CARNES HMJ R&D Center Inc Hyundai Capital Europe GmbH Rotem Equiptments (Beijing), etc. excluded (Total 58 companies) Kia Motor & 23 subsidiaries Hyundai HYSCO & 8 subsidiaries Hyundai Dymos & 3 subsidiaries Hyundai WIA & 5 subsidiaries Hyundai Powertech & 2 subsidiaries Hyundai Commercial, etc. Total Number of consolidated companies under K-GAAP (as of end of 2010): 95 companies (Equity Method affiliates: 42 companies) 19
20 K-IFRS vs. K-GAAP (Standalone) (KRW Billion) 1Q 2010 (K-GAAP) 1Q 2010 (K-IFRS) 1Q 2011 (K-IFRS) 비고 Sales Revenue 8, , ,326.2 Gross Profit 1, , ,279.1 Margin (%) SG&A 1, , ,384.7 Portion (%) Other Operating Income Operating Profit Margin (%) Recurring Profit 1, ,209.7 Margin (%) Net Profit 1, Margin (%)
21 Overseas Plant Operations
22 Overseas Plant : HMMA & BHMC (Unit : 1,000 vehicles / KRW Billion) US US Plant (HMMA) China Plant (BHMC) Sales Volume Revenue Sales Volume Revenue Sonata(YF) Elantra(MD) Santa-Fe(CM) Others Q 11 1Q Chg Elantra Tucson Sonata Others Q 11 1Q Chg Revenue 1,368 1,558 14% Revenue 2,262 2,933 30% Q Q Q Q 2011 Above figures are standalone results base 22
23 Overseas Plant : HMI & HAOS (Unit : 1,000 vehicles / KRW Billion) India Plant (HMI) Turkey Plant (HAOS) Sales Volume Revenue Sales Volume Revenue I10 PB Santro Others Accent Matrix i Revenue 10 1Q 1, Q 1,238 Chg -5% 20 Revenue 10 1Q Q 292 Chg 56% Q '10 1Q '11 1Q '10 1Q '11 Above figures are standalone results base 23
24 Overseas Plant : HMMC & HMMR (Unit : 1,000 vehicles / KRW Billion) Czech Plant (HMMC) Russia Plant (HMMR) Sales Volume Revenue Sales Volume Revenue i30 JC YN RBr Q 11 1Q Chg 10 1Q 11 1Q Chg Revenue % Revenue Q '10 1Q '11 1Q '10 1Q '11 Above figures are standalone results base 24
Telekom Austria Group Results for the 1st Quarter May 27, 2003
Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationFY2009 First Quarter Financial Results. SUZUKI MOTOR CORPORATION August 3, 2009
FY2009 First Quarter Financial Results SUZUKI MOTOR CORPORATION August 3, 2009 Consolidated: Financial Summary Page 2 FY2009 1Q FY2008 4Q 09/4-6 09/1-3 Change FY2008 1Q 08/4-6 Change (Billion Yen) (A)
More informationSummary Statement of Financial Position (consolidated)
2012. 5. 3. 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and is subject to updating, revision,
More informationDELICA D:5 ACTIVE GEAR 0
DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion
More informationSummary of Results for the First Half of FY2015/3
Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial
More informationKorean Airlines Q Results
Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and
More information1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes
1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements
More informationConsolidated: Financial Summary
FY2010 First Quarter Financial Results SUZUKI MOTOR CORPORATION 3 August 2010 Consolidated: Financial Summary Page2 FY2010 1Q FY2009 1Q (2010/4-6) (2009/4-6) Change Net sales 656.3 577.1 +79.2 +13.7% Operating
More informationEndesa 1Q 2017 Results 09/05/2017
Endesa 1Q 2017 Results 09/05/2017 1. Highlights and key financial figures 2. Endesa s performance in 1Q 2017 market context 3. Financial results 4. Final remarks 2 1. Highlights and key financial figures
More informationWelcome to LG Electronics
Welcome to LG Electronics April 21, 2004 As a note, this presentation has been prepared based on internal audited figures and final figures may change due to the results of independent auditors review.
More informationQ Investor Kit JANUARY-JUNE 2013
Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationQ Investor Kit JANUARY-JUNE 2014
Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationQ Investor Kit JANUARY-MARCH 2013
Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)
More informationQ Investor Kit JANUARY-MARCH 2014
Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco
More informationFor personal use only
Cochlear Limited Results for the half year ended 31 December 2011 (H1 F12) Chris Roberts, CEO Neville Mitchell, CFO Cochlear Overview Cochlear Limited (ASX:COH): global leader in implantable devices for
More informationQ Investor Kit January December 2014
Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationColoplast A/S. Investor presentation 1H 2005/06
Coloplast A/S Investor presentation 1H 2005/06 2 Coloplast Coloplast products and services help patients achieve greater independence from medical challenges in 4 areas: Ostomy care, continence care, wound
More informationCPH Chemie + Papier Holding AG. Investor Day. Perlen, 13 th September 2018
CPH Chemie + Papier Holding AG Investor Day Perlen, 13 th September 2018 Agenda 2.00 pm Welcome 2.05 pm Presentation Course of Business 2018 2.50 pm Break 3.00 pm Presentation Perlen Packaging 3.30 pm
More information1Q 2014 Earnings Release
1Q 2014 Earnings Release April 2014 DISCLAIMER Financial results for 1Q 2014 are provisional and accordingly subject to change according to the outside independent auditors review. This presentation contains
More informationResults Briefing. 15 ~ 17 May 2007
Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights
More informationFirst Quarter Results to March 31, Shire plc April 25, 2008
First Quarter Results to March 31, 2008 Shire plc April 25, 2008 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationFor personal use only
HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening
More informationBANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-
BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest
More informationQ2 INVESTOR KIT JANUARY-JUNE 2011
Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist
More informationThird-quarter results 2013
Third-quarter results 213 Fornebu, 6 November 213 Øyvind Eriksen and Leif Borge Agenda 213 Introduction Øyvind Eriksen Executive chairman Financials Leif Borge President & CFO Q&A Q&A session Øyvind Eriksen
More informationTHIRD QUARTER REPORT 2011 (UNAUDITED)
THIRD QUARTER REPORT 2011 (UNAUDITED) Kronprinsesse Märthas pl. 1, Vika, 0166 Oslo, Norway. Tel: + 47 23 01 09 60, www.bionorpharma.com Page 1 THIRD QUARTER REPORT 2011 HIGHLIGHTS On the 25th August Bionor
More informationPresentation of. Burgdorf, 1 st November 2012
Presentation of Semi-Annual Results 2012/13 Burgdorf, 1 st November 2012 Important Notice The information contained in this document has not been independently verified and no representation or warranty,
More informationWoongjin Coway. 1Q 12 IR Presentation
Woongjin Coway 1Q 12 IR Presentation Disclaimer This presentation contains historical information of the company which should not be regarded as an indication of the future performance or results. This
More informationFY2007 Consolidated Financial Overview
FY2007 Consolidated Financial Overview CHUGAI PHARMACEUTICAL CO., LTD. Executive Vice President and CFO Ryuzo Kodama January 30/31, 2008 Forward-Looking Statements This presentation may include forward-looking
More informationEnel Américas 1Q 2018 results
Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationInvestor Relations 1Q 2017
Investor Relations 1Q 2017 History Leading Authentic Sports Brand Inspired by the Style, Elegance and Passion of our Italian Heritage Founded by FILA brothers in Biella, Italy Established FILA Korea FILA
More informationM e d i a s e t G r o u p
M e d i a s e t G r o u p 11 th May 2004 2004 First Quarter Results M e d i a s e t G r o u p BROADCASTING MEDIASET 2004 1Q 24 Hours Audience Trend Individuals Share Points Vs 1Q 2003 OTHER SATELLITE 44.0%
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationSWEDISH MATCH RESULTS PRESENTATION Q3 2017
SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,
More informationAPPLIANCE TELECOMMUNICATIONS
May 2001 1 DEVICE CRT PDP CRT components APPLIANCE Air Conditioner Refrigerator Washing machine Cooking appliance DISPLAY& MEDIA TV / Monitor CD-ROM DVD products VCR / PC / PCB TELECOMMUNICATIONS Switching
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationRAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders
Contact: Investor Relations: Bob Bannon (336) 741-3359 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2016-22 RAI reports strong 2Q16 performance
More information1Q2017 法人說明會 Jun. 9, 2017
1Q2017 法人說明會 Jun. 9, 2017 FE group business Span over 10 major industries Own over 240 companies Established in 1937 9 public listed companies in Taiwan and HK Petrochemical & energy Polyester & synthetic
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationGroup financial results for the first quarter 2008
Helmut Perlet, Member of the Board of Management Group financial results for the first quarter 2008 Journalists Conference Call May 9th, 2008 Group: robust earnings in stormy weather (EUR mn) Quarterly
More informationSWEDISH MATCH RESULTS PRESENTATION Q4 2018
SWEDISH MATCH RESULTS PRESENTATION Q4 2018 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,
More informationValneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017
Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total
More informationAnnual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors
Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationJT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007
Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period
More informationFIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO
FIRST QUARTER 2018 RESULTS 15 MAY 2018 LUCA BETTONTE, CEO DISCLAIMER This document contains certain forward-looking information that is subject toa number of factors that may influence the accuracy of
More informationObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland
More informationQ Investor Kit January December 2015
Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local
More informationFY2016 1H Results. Cookpad Inc.
FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising
More informationLeading Intimate Healthcare. Investor presentation Q1 2007/08
Leading Intimate Healthcare Investor presentation Q1 2007/08 1 2 Agenda Introduction to Coloplast Q1 2007/08 in headlines Outlook for 2007/08 Strategic targets Leading intimate healthcare Appendices Q1
More informationTelekom Austria Group Results for the First Quarter May 16, 2007
Telekom Austria Group Results for the First Quarter 2007 May 16, 2007 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those
More informationMETVIX PDT ON THE MARKET IN GERMANY AND UK
METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone
More informationUroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011
Uroplasty, Inc. Investor Update Canaccord Genuity Conference December 6, 2011 Forward Looking Statement This presentation includes forward-looking statements, including financial projections, relating
More informationJT Group Consolidated Financial Results 2018 First Quarter Results
JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationReview of Half Year 2010
Aiming i to Become a Top Japanese Pharmaceutical Company Review of Half Year 2010 CHUGAI PHARMACEUTICAL CO., LTD. President and CEO Osamu Nagayama July 22/23, 2010 Forward-Looking Statementst t Aiming
More informationShareholder Presentation Annual Meeting 2018
Shareholder Presentation Annual Meeting 2018 FY 18 HIGHLIGHTS Strong sales growth of 2 nd Gen TruScreen to China commenced during 4 th quarter. (50% of the year s sales were generated in the fourth quarter)
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationMANAGEMENT. MGMT 0021 THE MANAGEMENT PROCESS 3 cr. MGMT 0022 FINANCIAL ACCOUNTING 3 cr. MGMT 0023 MANAGERIAL ACCOUNTING 3 cr.
MANAGEMENT MGMT 0021 THE MANAGEMENT PROCESS 3 cr. An introduction designed to emphasize the basic principles, practices, and terminology essential to the understanding of contemporary business and its
More informationGrowth in core businesses offsets weaker non-interest income. DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts
Growth in core businesses offsets weaker non-interest income April 29, 2005 DBS Group Holdings 1Q 2005 Financial Results Presentation to Media and Analysts This presentation is available at www.dbs.com/investor
More informationMARCH 2014 RESULTS PRESENTATION Madrid, 2014
MARCH 2014 RESULTS PRESENTATION Madrid, 2014 Disclaimer In addition to figures prepared in accordance with IFRS, PRISA presents non-gaap financial performance measures, e.g., EBITDA, EBITDA margin, adjusted
More informationELICA 2012 Q3 RESULTS. November 14,
ELICA ELICA 1 Q3 12 Highligths Negative market demand, showing better trend compared to previous quarters Group sales over performing in all major markets Cost reduction efforts and continued product innovation
More informationUCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth
Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth
More informationBusiness Results. for the First Quarter of FY2016/3. August 4, 2015 (Tue.) NH Foods Ltd.
Business Results for the First Quarter of FY216/3 August 4, 215 (Tue.) NH Foods Ltd. Contents Contents I. Consolidated Business Results for FY216/3 1Q (Apr. Jun.) II. Outlook for FY216/3 III. Consolidated
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationWalgreens (WAG) Analyst: Juan Fabres Fall 2014
Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores
More informationValneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company s Trend towards EBITDA Break-even
Valneva Reports Strong Revenue Growth and Positive EBITDA in H1 Confirming the Company s Trend towards EBITDA Break-even Financial performance of commercial products continued to improve in the second
More informationTotal Face Group Limited
Total Face Group Limited 2017 Half Year Results Presentation Contents Results Highlights Highlights Half Year Results Revenue Bridge Revenue Breakdown Clinic Profitability Profit & Loss Financial Position
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationInterim Report 1 January September 2017
2014-01-01 2014-12 Interim Report 1 January 2017 30 September 2017 Cantargia AB 556791-6019 Cantargia refers to Cantargia AB (publ), corporate ID number 556791-6019. Clinical trial initiated Highlights
More informationMorgan Stanley CEOs Unplugged January 3, Matthew Emmens, CEO Shire plc
Morgan Stanley CEOs Unplugged January 3, 2008 Matthew Emmens, CEO Shire plc Introduction Strategy on track Excellent third quarter results Strong product sales reflecting good results and successful product
More informationSWEDISH MATCH INVESTOR KIT Q4 2016
SWEDISH MATCH INVESTOR KIT Q4 2016 A look at the quarter 2 Q4 HEADLINE BULLETS Sales increased by 6 percent to 3,957 MSEK (3,719) for the fourth quarter and by 7 percent to 15,551 MSEK (14,486) for the
More informationNobel Biocare Group Full Year Report 2005
Nobel Biocare Group Full Year Report 2005 Zurich, Switzerland 9 February 2006 Nobel Biocare again outpaces market with record revenue growth of 25% and an EBIT margin of 33.5% in 2005 Revenue for the full
More informationSupplementary Data of Consolidated Financial Statements for the third quarter ended December 31, 2016
Supplementary Data of Financial Statements for the third quarter ended December 31, 2016 January 31, 2017 NITTO DENKO CORPORATION CONTENTS Page Business 1 Segment Information 2 Segment Information By Geographic
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2018 Win-Partners Co., Ltd. (3183) 2Q results ending September 2017 Consolidated results summary ( mil)2q to Sep 2016 Sep 2017 YoY OE Sales 27,713 29,753 +7.4% 29,500 Operating
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationObsEva Reports First Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109
More informationThromboGenics Business Update H1 2018
Press release 6 September 2018 Regulated Information ThromboGenics Business Update H1 2018 Positive Topline Results for Diabetic Eye Disease Portfolio Shareholder approval for company name change to Oxurion
More informationResults Presentation 2Q FY March Win-Partners Co., Ltd. (3183)
Results Presentation 2Q FY March 2019 Win-Partners Co., Ltd. (3183) 2Q results ending September 2019 3 Consolidated results summary ( mil)2q to Sep 2017 Sep 2018 YoY OE Sales 29,753 31,863 +7.1% 31,700
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationFor personal use only
FY2015 Half Year Results Presentation 6 months ended 30 September 2014 24 28 November 2014 1 First half result highlights H1 FY15 (6 months to 30 September 2014) PCP CC 1 Operating profit +8% +64% RAC
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationZealand Pharma A/S Interim report for Q (un-audited)
Company Announcement No. 12/2012 (un-audited) Net profit for the quarter of DKK 66 (EUR 9) million Important pipeline progress, and revenue from milestone payments of DKK 120 (EUR 16) million Cash and
More informationMorgan Stanley Global Consumer & Retail Conference New York, November 19, 2014
Morgan Stanley Global Consumer & Retail Conference New York, November 19, 2014 André Calantzopoulos Chief Executive Officer Philip Morris International Forward-Looking and Cautionary Statements This presentation
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationSpiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria
Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria FINANCIAL TIMES INVESTING IN BULGARIA CONFERENCE Investment Opportunities in Bulgaria The Case of Solvay Sodi Spiros Nomikos CEO of Solvay Sodi
More informationThird Quarter Results to September 30, 2009
Third Quarter Results to September 30, 2009 Shire plc October 30, 2009 Angus Russell Chief Executive Officer Graham Hetherington Chief Financial Officer Michael Cola President, Specialty Pharmaceuticals
More informationBALCHEM CORPORATION. Q Investor Relations Presentation
BALCHEM CORPORATION Q4 2017 Investor Relations Presentation Balchem Corporation Balchem develops, manufactures, and markets specialty ingredients that improve and enhance the health and well being of life
More informationPIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015
PIRELLI 1Q 2015 RESULTS MILANO MAY 13, 2015 KEY MESSAGES AGENDA 1Q 2015 RESULTS 2015 OUTLOOK & TARGETS 1Q 2015 TYRE OVERVIEW APPENDIX 1Q 2015 RESULTS 1 KEY MESSAGES > A solid 1Q 2015 with Premium outperformance
More information1Q 2015 Results A Positive Start to 2015
1Q 2015 Results Main Events Operating Results Order Backlog Financial Performance Update on Disposal 1Q 2015 Results A Positive Start to 2015 Rome - May 14, 2015 1Q 2015 Main Backlog Events 1Q 2015 Results
More informationartnet AG Quarterly Interim Statement for the First Quarter of 2016 artnet AG Quarterly Interim Statement for the First Quarter of 2016
Quarterly Interim Statement for the First Quarter of 2016 Quarterly Interim Statement for the First Quarter of 2016 for Table of Contents General Information and Business Activities Economic Development
More informationFinancial Report on Zurich March 28, 2013
Financial Report on 2012 Zurich March 28, 2013 1 Safe Harbour Statement This presentation may include forward-looking statements that are based on our management s beliefs and assumptions and on information
More informationRAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance
Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance
More information